News
Bionote Redoubles Efforts to Expand Further into the US Market

 DISCLAIMER: This news article is a direct translation of the original Korean article from Pharm News. BioNote Inc. does not claim any right to the article or claim any ownership.

The translation was completed by BioNote Inc. only for the convenience of non-Korean speaking customers and BioNote Inc. does not seek to redistribute nor acquire profit from the translation.

- ​Bionote USA attends 'WVC 2023', the largest veterinary conference held in the US
- ​Focus on Veterinary Diagnostic Analyzers such as Vcheck F and Vcheck M




Leading global biological raw material and animal diagnostics company BIONOTE is continuing its efforts to expand further into the US market.

Bionote announced on the 28th, that its US Branch, BIONOTE USA (established in 2019), participated in the 'Western Veterinary Conference 2023' ("WVC") held in Las Vegas, NV, from the 19th of February to the 22nd of February and carried out extensive promotional and marketing activities.

WVC is the largest veterinary conference, in terms of scale, held in the US and veterinary experts as well as companies from around the world meet to share their insight, latest innovations in animal related products/services.

According to Bionote, their US counterpart actively promoted their Vcheck F immunodiagnostic analyzers (V200, V2400), as well as the newly developed equine progesterone, SAA and IgG biomarkers, at the event.

Furthermore, BIONOTE USA also promoted the newly released POC molecular diagnostic analyzer, Vcheck M, which is capable of nucleic acid amplification and quantitative analysis for the detection and diagnosis of major infectious diseases. Vcheck M is intuitive to use, even without much training, for performing PCR on site with the results being ready within only 1 hour, explained Bionote.

A Bionote spokesperson said, "We plan on continuing our marketing and promotional activities in future conferences and events" and that "Bionote will continue to expand our market share by introducing our molecular diagnostic products and clinical chemistry products along with our usual immunodiagnostic products, showcasing our diverse product portfolio to the global market".